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In 2018, some sartan medicinal products were reported to be contaminated with nitrosamine compounds, which are potent 
mutagenic carcinogens. Two nitrosamines received particular attention: N-nitrosodimethylamine (NDMA) and 
N-nitrosodiethylamine (NDEA). These have since been confirmed in different types of medicinal products, including 
ranitidine and metformin. Consequently, the European Medicines Agency (EMA) started an investigation into the cause 
of contamination and an assessment of the risk to patients taking contaminated medicinal products. The main source of 
contamination were changes in production, which involves combinations of amines and nitrogen compounds and the use 
of specific catalysts and reagents. Withdrawals of medicinal products that took place in Croatia did not lead to a shortage 
of sartan- or metformin-containing medicines. Moreover, ranitidine had been preventively withdrawn all over the EU, 
including Croatia, creating shortages at the time, but was subsequently replaced with therapeutic alternatives.
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Nitrosamines are a group of organic compounds 
containing the nitroso functional group. They can be found 
in water, food, tobacco, pesticides, or plastics, but received 
public attention in mid-2018, when they were also found 
in medicinal products (1).
Among them, N-nitrosamines are so potent mutagenic 
carcinogens that they are referred to as the “cohort of 
concern” by the International Council for Harmonisation 
of Technical Requirements for Pharmaceuticals for Human 
Use (ICH) guideline on assessment and control of DNA 
reactive (mutagenic) impurities in pharmaceuticals to limit 
potential carcinogenic risk (2). The two best-known 
nitrosamines, N-nitrosodimethylamine (NDMA) and 
N-nitrosodiethylamine (NDEA), have been classified by 
the International Agency for Research on Cancer (IARC) 
as possible human (class 2A) carcinogens, but they are also 
genotoxic (3, 4). Once N-nitrosamines are activated by 
microsomal liver enzymes, they can react with DNA base 
pairs to form unstable α-hydroxyalkylnitrosamines and 
produce alkyldiazonium ions, which alkylate DNA bases 
and induce carcinogenic response (5).
Discovery of nitrosamines in medicinal products
On 6 June 2018, active pharmaceutical ingredient (API) 
manufacturer Zhejiang Huahai Pharmaceutical (ZHP) from 
China detected NDMA contamination in the manufacturing 
process of valsartan. Investigation showed that nitrosamine 
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contaminants in the ZHP plant appeared after July 2012, 
when parts of valsartan production changed to increase 
yields and reduce waste. More specifically, the manufacturer 
changed the synthetic process involving tetrazole ring 
formation by replacing tributyltin azide with a more toxic 
anhydrous sodium azide, while dimethylformamide (DMF) 
was used as the solvent. Sodium nitrite, which forms nitrous 
acid in an acidic medium, was used to quench the excess 
sodium azide, which resulted in the nitrosation of 
d i m e t h y l a m i n e  ( D M A )  i m p u r i t y  p r e s e n t  i n 
dimethylformamide to form NDMA (Figure 1) (6).
Regulatory response
In response to that discovery, medicines agencies of the 
member states of the European Union (EU) withdrew a 
series of medicines containing valsartan API manufactured 
by ZHP. On 5 July 2018, the European Commission (EC) 
put the Committee for Medicinal Products for Human Use 
(CHMP) of the European Medicines Agency in charge of 
assessing valsartan medicines in the EU that contained the 
ZHP-manufactured API, pursuant to Article 31 of the 
Directive 2001/83/EC on the Community code relating to 
Figure 1 Production changes that caused formation of NDMA in 
the Zhejiang Huahai Pharmaceutical plant (6)
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medicinal products for human use (7). In the following 
weeks, the presence of another nitrosamine, NDEA, was 
also confirmed in certain products. Furthermore, 
investigations showed that N-nitrosamine contamination 
was not limited to the ZHP plant and valsartan API 
production but also affected other sartans containing 
tetrazole rings (Figure 2). That discovery widened the 
assessment to all sartans with a tetrazole ring (6, 8).
On 31 January 2019, the CHMP concluded its review 
and published a final retrospective risk assessment (9) taking 
into account that every second person in the EU is at risk 
of developing cancer during their lifetime. Preliminary 
assessments included nitrosamine exposure from other 
sources and extrapolated risk results from animal studies. 
The worst-case scenario of the final risk assessment was 
that if 100,000 patients took the highest dose (320 mg) of 
valsartan manufactured by ZHP (which had the highest 
levels of contamination) every day for six years (that is, 
since 2012, when the production process was changed), that 
could lead to 22 additional cases of cancer due to NDMA 
over their lifetime. NDEA impurities, in turn, could lead to 
eight additional cancer cases per 100,000 patients if they 
took valsartan in the highest dose every day for four years. 
As for sartans containing the tetrazole ring, the review 
reported that a vast majority had no nitrosamine impurities 
or these were detected in very small amounts (9).
Having identified the sources of N-nitrosamine 
contamination (Table 1), the CHMP considered short- and 
long-term measures to address the issue. In the short term, 
it set temporary limits for NDMA and NDEA impurities in 
APIs based on maximum daily intake of 96.0 ng and 
26.5 ng, respectively, derived from animal testing and 
calculated according to ICH M7 (R1) methodology (linear 
extrapolation of cancer potency metrics). These limits 
should apply over a two-year transition period following 
the Commission’s decision adopted on 2 April 2019. During 
this period, marketing authorisation holders (MAHs) are to 
assess the risk of contamination and ensure that control 
strategies are in place for the batches of sartan APIs used 
in their finished products. In the long term, all MAHs 
concerned must make the necessary changes in API 
production to minimise nitrosamine contamination. In the 
meantime, the temporary limits will be used to recall sartans 
that exceed them from national markets (4, 6, 8, 9).
In 2019, NDMA and NDEA were also found in 
ranitidine and metformin. When quality testing showed that 
some of ranitidine medicines contained NDMA in higher 
concentrations than the acceptable daily intake limit, EMA 
in September 2019 started another review of medicinal 
products containing ranitidine, which led to a conclusion 
that MAHs should extend their risk evaluation to all 
medicinal products containing a chemically synthesised 
active substance (3). As for metformin, EMA review is still 
ongoing as it awaits further test results from Official 
Medicines Control Laboratories (OMCLs) (10).
Carcinogenicity
The carcinogenicity of NDMA and NDEA stems from 
their biotransformation via microsomal liver enzymes, 
primarily CYP2E1, to their respective alkyl diazonium ions. 
These ions react with the DNA and form DNA adducts, 
which cause endogenous DNA damage (6, 8–11).
Figure 2 Sartans with a tetrazole ring contaminated with impurities (4)
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Table 1 The most common sources of NDMA and NDEA impurities in medicinal products (3, 4, 6). 













(DMA) reagent / solvent
NDEA NaNO2









The use of azide reagents in the synthesis of tetrazole, under the acidic conditions required for the 
isolation and extraction of tetrazole, releases the dangerous hydrazoic acid which can give e.g. amines. 
The remaining amounts of azide can be decomposed into gaseous by-products such as nitrogen and 
nitrous oxide (N2O) by the addition of sodium nitrite (NaNO2).
Faults in the 
production 
process
Inappropriate or poorly controlled reaction conditions concerning temperature, pH, or the order of 




If the solvents used in the reaction step involving azide are collected and reused, there is a possibility 
that nitrosamines may be inadvertently introduced into the production process if the waste stream is 
quenched with nitrite in the presence of secondary or tertiary amines and subsequently treated with 
nitric acid, e.g. to destroy residual azides without adequate process control. There is also a possibility 
that the process water used in the production of the API may contain low levels of nitrosamines due to 
environmental pollution.
Third-party
External recovery companies do not receive sufficiently specific information on the composition of the 
materials they process and they use routine processing procedures and generally accepted equipment. 
This can lead to cross-contamination of solvents, reagents, and catalysts (originating from different 
sources and processes) if the equipment is not properly cleaned between customer orders or if precautions 
are not taken to prevent the formation of nitrosamines.
Contaminated 
raw materials and 
intermediates
Distributors using recovered materials or raw materials that contain nitrites or amines and whose 
processing can lead to the formation of nitrosamines. Problematic if an API manufacturer who 
exclusively uses nitrosamine-free processes is not aware that there is a risk of nitrosamine formation.
Sources of nitrosamine contamination of finished products
Use of certain 
packaging 
materials





NDMA Nitrocellulose (on lidding foil) Printing ink
Dimethylamine 
(DMA)
Lidding foil / 
printing ink
NDEA Nitrocellulose (on lidding foil) Printing ink
Diethylamine 
(DEA)




Some stored medicinal products may undergo degradation pathways that form nitrosamine impurities. 
The chemical structure of metformin also indicates the possibility of subsequent nitrosamine formation 
during storage. The formation of metformin hydroperoxide can lead to the oxidation of other metformin 
molecules or the formation of nitrosamines by intramolecular oxidation, which leads to rearrangements 
and fragmentation reactions. Due to the high nitrogen content in metformin, numerous positions 
for N-oxidations are possible. Besides, numerous fragmentation reactions enable decomposition of 





In vitro studies of different pH solutions of ranitidine with and without nitrite have shown the possibility 
of NDMA formation from ranitidine in acidic gastric pH in the presence of high levels of nitrites, which 
nitrosate the diamine part of the ranitidine molecule.
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Nitrosamine exposure can be either endogenous or 
exogenous. Exogenous exposure can result from consuming 
food or beverages (e.g., beer), inhaling tobacco smoke, or 
using rubber items and cosmetics. Endogenous exposure is 
the result of nitrosation of nitrosamine precursors in the 
stomach. Quantification of endogenous N-alkylnitrosamine 
formation and its contribution to total N-nitrosamine 
exposure was extensively studied years ago (3, 12), and 
there is no recent research on intragastric formation of 
NDMA/NDEA from complex mixtures of precursors and 
inhibitors in humans.
It is important to note that the target organs of NDMA/
NDEA toxicity and tumours may differ between species. 
Although nitrosamine metabolism takes place in the liver, 
it is not concentrated in the liver, and according to studies 
performed in rats (6, 13), only about 1 %, is excreted 
unchanged in the urine. The target organs of NDMA and 
NDEA in humans are still unknown, but several human 
studies have shown a risk of developing nitrosamine-related 
cancer, stomach in particular.
Causes of NDMA and NDEA impurities in medicinal 
products
N-Nitrosamines can form in the presence of certain raw 
materials (including starting materials and intermediates) 
under suitable reaction conditions and may end up in the 
final product if  purification in the various stages of 
production is incomplete (3, 4).
According to the CHMP review of sartans (4), the 
formation of N-nitrosamine in the API was caused by the 
reaction of NaNO2 – a common source of NOx – with 
different sources of secondary and tertiary amines. In 
addition to these causes for sartan impurities, Table 1 lists 
other possible causes of nitrosamine contamination/
formation in metformin and ranitidine.
The situation on the Croatian market
Medicinal products containing sartans with tetrazole 
rings (valsartan, losartan, olmesartan, irbesartan), 
candesartan, or metformin are still present on the Croatian 
market. Withdrawal of certain product batches did not 
jeopardise regular supply, because medicines manufactured 
by other manufacturers were not affected by withdrawals 
(14).
However, ranitidine, which had been available as over-
the-counter (OTC, non-prescription) or prescription 
medicine, has been withdrawn from the Croatian market 
since September 2019 (15, 16), when EMA’s assessment 
of ranitidine started. All ranitidine products in Croatia were 
recalled as a precautionary measure. Other EU countries 
have done the same for as long as the EC decision is 
pending. Ranitidine withdrawal has created a shortage, i.e. 
a permanent interruption in the supply of the Croatian 
market, and the patients have been provided replacement 
therapy.
Before withdrawal, ranitidine was among the 50 most 
used medicinal products in Croatia and reached its peak in 
2018, when ranked 31st.
Although valsartan is still available on the market, it 
has seen a major decline in its consumption since 2018, 
when it ranked 25th. Namely, in 2019 it dropped to the 37th 
place (17, 18).
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Nitrozaminska onečišćenja u lijekovima
Nitrozaminski su spojevi jaki kancerogeni i njihova je prisutnost potvrđena 2018. u nekim lijekovima s djelatnom tvari 
iz skupine sartana. Dva predstavnika nitrozamina, najčešće detektirana kao onečišćenja u lijekovima, jesu 
N-nitrozodimetilamin (NDMA) i N-nitrozodietilamin (NDEA). Od tada je njihova prisutnost potvrđena u različitim 
skupinama lijekova, što upućuje na njihovu učestalost. Slijedom toga, Europska agencija za lijekove (EMA) pokrenula 
je istragu uzroka onečišćenja te procjenu rizika kojima su pacijenti koji su uzimali lijekove onečišćenih serija bili izloženi. 
Glavni uzrok onečišćenja djelatne tvari uključuje promjene u proizvodnom postupku koji sadržava smjesu amina i 
dušikovih spojeva uz uporabu specifičnih katalizatora i reagensa. Nitrozamini su također pronađeni u gotovim lijekovima. 
Povlačenje lijekova u Hrvatskoj nije dovelo do nestašice lijekova koji sadržavaju sartan ili metformin, a lijekovi koji 
sadržavaju ranitidin povučeni su iz mjera opreza iz ljekarni i u Hrvatskoj i u Europskoj uniji.
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